This site is intended for health professionals only!

Published on 1 March 2007

Share this story:

Recent advances in the treatment of myelodysplastic


Michel Delforge MD PhD
Assistant Professor of Haematology
Department of Haematology
University Hospital Leuven

The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal myeloid haemopathies with a complex underlying pathogenesis. MDS is a common haematological disorder that primarily affects the ageing population. Its clinical presentation is related to progressive bone marrow failure, but around 40% of the MDS population also has an increased risk for leukaemic transformation.(1,2) The International Prognostic

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine